Cumberland Pharmaceuticals Inc. (CPIX)
NASDAQ: CPIX · Real-Time Price · USD
3.130
+0.080 (2.62%)
Mar 24, 2026, 4:00 PM EDT - Market closed
CPIX Revenue
In the year 2025, Cumberland Pharmaceuticals had annual revenue of $44.52M with 17.57% growth. Cumberland Pharmaceuticals had revenue of $13.68M in the quarter ending December 31, 2025, with 31.08% growth.
Revenue (ttm)
$44.52M
Revenue Growth
+17.57%
P/S Ratio
1.05
Revenue / Employee
$478,725
Employees
93
Market Cap
46.81M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 44.52M | 6.65M | 17.57% |
| Dec 31, 2024 | 37.87M | -1.68M | -4.26% |
| Dec 31, 2023 | 39.55M | -2.46M | -5.85% |
| Dec 31, 2022 | 42.01M | 6.03M | 16.75% |
| Dec 31, 2021 | 35.99M | -1.46M | -3.89% |
| Dec 31, 2020 | 37.44M | 3.05M | 8.88% |
| Dec 31, 2019 | 34.39M | 5.04M | 17.19% |
| Dec 31, 2018 | 29.34M | -11.81M | -28.69% |
| Dec 31, 2017 | 41.15M | 8.12M | 24.60% |
| Dec 31, 2016 | 33.03M | -493.49K | -1.47% |
| Dec 31, 2015 | 33.52M | -3.38M | -9.17% |
| Dec 31, 2014 | 36.90M | 4.87M | 15.22% |
| Dec 31, 2013 | 32.03M | -16.82M | -34.44% |
| Dec 31, 2012 | 48.85M | -2.29M | -4.48% |
| Dec 31, 2011 | 51.14M | 5.27M | 11.48% |
| Dec 31, 2010 | 45.88M | 2.34M | 5.37% |
| Dec 31, 2009 | 43.54M | 8.46M | 24.13% |
| Dec 31, 2008 | 35.08M | 7.01M | 24.98% |
| Dec 31, 2007 | 28.06M | 10.25M | 57.52% |
| Dec 31, 2006 | 17.82M | 7.13M | 66.66% |
| Dec 31, 2005 | 10.69M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rockwell Medical | 75.58M |
| InterCure | 72.16M |
| Aytu BioPharma | 62.64M |
| BGM Group | 25.10M |
| Zhengye Biotechnology Holding | 21.46M |
| SCYNEXIS | 20.60M |
| TherapeuticsMD | 2.80M |
| BioXcel Therapeutics | 752.00K |
CPIX News
- 7 days ago - Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting - PRNewsWire
- 21 days ago - CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH - PRNewsWire
- 4 weeks ago - Joint U.S. Commercialization of RedHill's Talicia® Commences - PRNewsWire
- 4 weeks ago - CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA® - PRNewsWire
- 4 weeks ago - CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE - PRNewsWire
- 6 weeks ago - Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program - PRNewsWire
- 3 months ago - CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT - PRNewsWire
- 5 months ago - CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH - PRNewsWire